Corcept is evolving from a single-product endocrinology story into a two-franchise biopharma company, with Lifyorli adding a new growth engine. The stock looks fairly valued after strong Q2 revenue growth, but execution risk and a young launch keep the rating at Hold.
Corcept Therapeutics(CORT) has moved from a single-product endocrinology company toward a two-franchise biopharma business. Q2 2026 revenue rose 31.7% year over year to $256.1M, including $208.6M from Korlym and its authorized generic and $47.6M from newly launched Lifyorli. Management also raised 2026 revenue guidance to $1.1B-$1.2B. The central investment case is that Lifyorli's early launch can diversify revenue while the existing Cushing's syndrome business continues to expand.
The growth evidence is strong but the valuation leaves less room for execution mistakes. CORT's forward P/E is 14.4x and its PEG ratio is 0.8x, while its trailing P/E is 194.6x because current trailing earnings remain depressed relative to forward estimates. Q2 net income reached $43.0M, but first-half 2026 net income was $11.2M versus $55.7M in the prior-year period. That contrast captures the opportunity and the risk: the launch is working, but profitability still depends on sustained revenue growth and disciplined spending.
For a moderate-risk investor with a medium-term horizon, CORT merits a Hold recommendation. The company has a strong balance sheet, substantial clinical and commercial assets, and several regulatory catalysts. However, Lifyorli's launch remains young, relacorilant's Cushing's indication carries a December 17, 2026 PDUFA date after a prior complete response letter, and insider transactions show meaningful selling. The report's fair value estimate of $120 gives credit for growth without treating every pipeline program as a commercial success.
Corcept Therapeutics(CORT), headquartered in Redwood City, California, is a commercial-stage biopharmaceutical company founded in 1998 and listed on Nasdaq. Its research and commercial strategy centers on modulating the glucocorticoid receptor, or GR, to treat disorders involving excess cortisol activity. The company reported 730 employees and operates across endocrinology, oncology, metabolic disease, and neurology.
The business is built around a focused scientific platform rather than a broad collection of unrelated drug candidates. CORT says it has discovered more than 1,000 proprietary cortisol modulators. Its lead assets include relacorilant, nenocorilant, miricorilant, and dazucorilant, with programs spanning Cushing's syndrome, solid tumors, MASH, and ALS.
CORT reports one operating segment covering the discovery, development, and commercialization of pharmaceutical products. The practical economic breakdown is therefore by product franchise. In Q2 2026, Korlym and the authorized generic generated $208.6M, while Lifyorli generated $47.6M in its first quarter of availability.
The endocrinology franchise remains the revenue base. Q2 Cushing's products grew from the prior-year period, and management reported record new prescriptions, first-time prescribers, and patients receiving treatment. CATALYST found hypercortisolism in 23.8% of 1,057 patients with difficult-to-control diabetes. MOMENTUM screened more than 1,000 patients with resistant hypertension and found hypercortisolism in 27% of that population.
Oncology is the growth engine. Lifyorli had reached more than 1,300 patients and more than 1,000 prescribing physicians by July 29, 2026. The product was added to NCCN guidelines as a preferred regimen 15 days after FDA approval, and more than 70% of combined Medicare, Medicaid, and commercial lives had formal coverage policies in place at that time.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Lifyorli is now CORT's flagship growth product. The FDA approved it on March 25, 2026, and the first capsules were sold on April 1. In the ROSELLA Phase 3 trial, relacorilant plus nab-paclitaxel reduced the risk of disease progression by 30% versus nab-paclitaxel alone, with a hazard ratio of 0.70 and a p-value of 0.008. The trial also showed a 35% reduction in the risk of death, with a hazard ratio of 0.65.
The clinical profile supports commercial adoption. ROSELLA's median overall survival was 16.0 months with relacorilant versus 11.9 months with nab-paclitaxel alone. The company reported that the survival benefit occurred across clinically relevant subgroups and without an increased safety burden. Oral administration, no biomarker requirement, preferred-guideline status, and broad early payer coverage provide Lifyorli with useful launch advantages.
Korlym remains the cash-generating foundation. In CATALYST, Korlym reduced HbA1c by 1.47% over 24 weeks versus 0.15% for placebo, while also producing a 5.1 kg reduction in body weight and a 5.1 cm reduction in waist circumference. Its weakness is structural: mifepristone binds to the progesterone receptor, and generic competition from Teva has been present since January 2024.
CORT's principal advantage is its specialized GR platform. The company has developed selective cortisol modulators that bind to the GR without meaningful affinity for progesterone, estrogen, or androgen receptors. That distinction gives relacorilant a clinical profile that avoids several adverse effects associated with mifepristone, including hypokalemia, endometrial thickening, vaginal bleeding, adrenal insufficiency, and QT prolongation.
The intellectual property portfolio adds protection. CORT reports U.S. and foreign patents covering selective cortisol modulators and their uses, with expiration dates ranging from 2028 to 2042 for key composition patents. Hypercortisolism patents covering proprietary selective modulators extend from 2033 to 2040, while oncology patents extend from 2033 to 2042.
The platform also creates multiple clinical shots on goal. CORT is testing relacorilant in ovarian, endometrial, cervical, pancreatic, and prostate cancers. Miricorilant is in the 175-patient MONARCH Phase 2b MASH trial, and dazucorilant is moving through a dose-titration study after DAZALS showed an 84% reduction in one-year mortality risk at the 300 mg dose, with a p-value of 0.09. These programs create upside, but they remain clinical assets rather than established revenue streams.
CORT relies on contract manufacturers for active pharmaceutical ingredients, tablets, and bottling. The company has purchased and holds significant quantities of mifepristone API. Its clinical work relies on contract research organizations, including Syneos Health for ROSELLA and BELLA and Medpace Research for MOMENTUM and MONARCH.
Distribution uses specialty pharmacies and specialty distributors. Nearly 100% of the Cushing's business flows through specialty pharmacies, where revenue is recognized when the patient receives the medicine. About 30% of oncology revenue flows through specialty pharmacies, with the balance handled by specialty distributors. Distributors hold roughly one week of demand, limiting the risk that channel inventory materially inflated Q2 results.
The specialty-pharmacy transition from Optime Care to Curant Health Georgia was substantially completed after the first quarter of 2026. Management said the transition was behind the company and that Q2 growth reflected new and existing patients rather than a material inventory contribution. That removes one operational overhang, although contract manufacturing, API sourcing, and specialty-drug reimbursement remain important execution points.
CORT operates in specialty pharmaceutical markets where diagnosis, guideline adoption, payer access, and physician education determine treatment volume. The Cushing's opportunity is expanding through better screening. CATALYST identified hypercortisolism in 23.8% of patients with difficult-to-control diabetes, while MOMENTUM identified it in 27% of patients with resistant hypertension. Among patients with both resistant diabetes and resistant hypertension, the prevalence figures reached 39.7% in CATALYST and 32.6% in MOMENTUM.
The oncology market offers a larger commercial runway but a tougher competitive environment. Lifyorli's ROSELLA results provide a survival-based selling point in platinum-resistant ovarian cancer, and its preferred NCCN status supports physician use. Management has stated a goal of more than $1B in annual U.S. Lifyorli revenue for platinum-resistant ovarian cancer and at least $2B in annual revenue from the current Cushing's business by the end of the decade.
The broader pharmaceutical market is projected at $1.89T in 2026 with a 6.7% projected compound annual growth rate through 2031. That industry growth is less important to CORT than the specific expansion of specialty therapies, oncology treatment, and diagnosis of underrecognized endocrine disease. CORT's 31.7% Q2 revenue growth is running well above the broader pharmaceutical market growth rate.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
CORT sells through physicians who treat complex endocrine and oncology patients. In endocrinology, the target population includes patients with difficult-to-control diabetes, resistant hypertension, and confirmed or suspected hypercortisolism. The CATALYST and MOMENTUM findings support a physician-education model because many patients present with symptoms that resemble more common metabolic and cardiovascular conditions.
Lifyorli's customer base is broader. More than 1,000 physicians had prescribed it to at least one patient by July 2026, including gynecologic, medical, and hematology oncologists. Prescriptions came from academic hospitals, community oncology clinics, and non-teaching hospitals. The number of patients started exceeded 1,300, giving CORT an early base from which to build repeat use.
Payers are also central customers in practice. More than 70% of combined Medicare, Medicaid, and commercial lives had a formal Lifyorli coverage policy in place by July 2026. CORT also operates patient-support programs and funds independent charitable foundations for hypercortisolism care, a structure that supports access while adding administrative and reimbursement complexity.
In Cushing's syndrome, CORT competes with Recordati's Isturisa and Signifor, Xeris Biopharma's Recorlev, Teva's generic Korlym, off-label ketoconazole and metyrapone, surgery, and radiation. The generic Korlym launch directly pressures the established franchise. CORT's response is to build relacorilant as a selective GR modulator with fewer progesterone-related and cortisol-synthesis-related safety concerns.
In ovarian cancer, Lifyorli competes with established chemotherapy combinations and other treatments used after platinum resistance. Its ROSELLA survival result, oral dosing, and lack of a biomarker requirement provide concrete differentiation. Preferred NCCN status 15 days after approval strengthens that position, although the product still needs to prove durable prescribing behavior beyond its first launch quarters.
CORT's competitive advantage is therefore specific rather than universal. It has deep expertise and intellectual property in cortisol modulation, but it does not have the scale, diversified revenue base, or broad commercial infrastructure of large pharmaceutical companies. The company must keep converting clinical evidence into guideline adoption, payer coverage, and repeat prescriptions.
Specialty pharmaceutical companies face a policy environment shaped by pricing scrutiny, generic competition, and regulatory review. Industry survey data identified generic and biosimilar competition as a concern for 37% of life-sciences respondents, while patent cliffs were cited by 26%. Those pressures are directly relevant to CORT because generic Korlym has competed since 2024.
CORT's contract manufacturing and API model creates exposure to supply-chain disruptions, regulatory changes, and trade policy. The company holds significant mifepristone API inventory, which provides a buffer for the legacy franchise. Lifyorli's commercial launch also increases the importance of reliable production, distribution, and reimbursement execution across specialty pharmacies and hospital channels.
Regulatory decisions are unusually important to the medium-term outlook. The FDA accepted CORT's relacorilant resubmission for Cushing's syndrome and assigned a December 17, 2026 PDUFA date. The original application received a complete response letter on December 30, 2025. That sequence makes the upcoming decision a material valuation event rather than a routine administrative step.
Corcept earns an A- on balance sheet health, reflecting a strong financial position that gives it room to fund launch and pipeline execution.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 revenue rose 31.7% year over year to $256.1M, but first-half 2026 net income of $11.2M shows profitability is still uneven.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised 2026 revenue guidance to $1.1B-$1.2B, signaling confidence in both Korlym and Lifyorli momentum.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 14.4x forward earnings and a 0.8x PEG, CORT looks reasonable, though its 194.6x trailing P/E shows how dependent the story is on forward growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value estimate is $120, leaving upside only if Lifyorli scales quickly and relacorilant clears its December 17, 2026 PDUFA.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Corcept Therapeutics(CORT) has a credible growth platform backed by commercial revenue, high gross margins, positive annual free cash flow, and minimal debt. Q2 2026 provided the clearest evidence that the strategy is working: revenue reached $256.1M, Lifyorli contributed $47.6M in its first quarter, and management raised full-year revenue guidance to $1.1B-$1.2B.
The next phase depends on conversion. CORT must turn Lifyorli's early patient and prescriber adoption into repeat revenue, navigate generic pressure on Korlym, and secure a favorable relacorilant decision for Cushing's syndrome after the December 17, 2026 PDUFA date. Its pipeline in MASH, ALS, and additional solid tumors adds optionality, but those programs belong in the upside case rather than the base case.
The result is a strong company with a demanding execution schedule. A Hold rating at a $120 fair value estimate balances the company's 31.7% revenue growth, 14.4x forward P/E, 0.8x PEG ratio, and strong liquidity against mixed earnings consistency, regulatory history, and a product portfolio still concentrated in a few key assets.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Corcept has a strong commercial base, a newly approved oncology product, and raised 2026 guidance, but the stock still screens as expensive. The report lands on a Hold as earnings pressure and execution risk offset the long-term growth story.
Corcept Therapeutics Incorporated (CORT) jumps after hours as investors react to its Q2 2026 earnings event and a fresh price-target hike from Canaccord Genuity. The stock moved sharply above its prior 52-week high, but valuation remains stretched and analyst views are sharply divided.
SK hynix Inc. (SKHY) rises sharply as Korean semiconductor shares rebound, boosted by strong export data, foreign buying, and renewed AI-memory demand. The move is supported by record operating profit and a low valuation, though average volume suggests this was not a confirmed breakout.